These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
517 related articles for article (PubMed ID: 27666115)
21. Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists. van Overbeeke E; De Beleyr B; de Hoon J; Westhovens R; Huys I BioDrugs; 2017 Oct; 31(5):447-459. PubMed ID: 28929342 [TBL] [Abstract][Full Text] [Related]
22. Biosimilars in the therapy of inflammatory bowel diseases. Hlavaty T; Letkovsky J Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561 [TBL] [Abstract][Full Text] [Related]
23. The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. Feagan BG; Marabani M; Wu JJ; Faccin F; Spronk C; Castañeda-Hernández G Adv Ther; 2020 Nov; 37(11):4491-4518. PubMed ID: 32910420 [TBL] [Abstract][Full Text] [Related]
24. Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Inotai A; Prins CPJ; Csanádi M; Vitezic D; Codreanu C; Kaló Z Expert Opin Biol Ther; 2017 Aug; 17(8):915-926. PubMed ID: 28650704 [TBL] [Abstract][Full Text] [Related]
25. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. Solitano V; D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S Expert Rev Clin Immunol; 2020 Oct; 16(10):1019-1028. PubMed ID: 32954893 [TBL] [Abstract][Full Text] [Related]
26. Clinical trial development for biosimilars. Alten R; Cronstein BN Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550 [TBL] [Abstract][Full Text] [Related]
27. Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance. Scherlinger M; Germain V; Labadie C; Barnetche T; Truchetet ME; Bannwarth B; Mehsen-Cetre N; Richez C; Schaeverbeke T; Joint Bone Spine; 2018 Oct; 85(5):561-567. PubMed ID: 29154920 [TBL] [Abstract][Full Text] [Related]
28. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Rinaudo-Gaujous M; Paul S; Tedesco ED; Genin C; Roblin X; Peyrin-Biroulet L Aliment Pharmacol Ther; 2013 Oct; 38(8):914-24. PubMed ID: 24001128 [TBL] [Abstract][Full Text] [Related]
29. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. Gisbert JP; Chaparro M Gastroenterol Hepatol; 2018; 41(6):389-405. PubMed ID: 29753532 [TBL] [Abstract][Full Text] [Related]
32. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876 [TBL] [Abstract][Full Text] [Related]
33. The nocebo effect challenges the non-medical infliximab switch in practice. Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188 [TBL] [Abstract][Full Text] [Related]
34. Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System? Gonczi L; Ilias A; Kurti Z; Lakatos PL Curr Pharm Des; 2019; 25(1):13-18. PubMed ID: 30864504 [TBL] [Abstract][Full Text] [Related]
35. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies. Phan DB; Elyoussfi S; Stevenson M; Lunt M; Warren RB; Yiu ZZN JAMA Dermatol; 2023 Jul; 159(7):763-771. PubMed ID: 37256582 [TBL] [Abstract][Full Text] [Related]
36. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. Radin M; Sciascia S; Roccatello D; Cuadrado MJ BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633 [TBL] [Abstract][Full Text] [Related]
37. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients. Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273 [TBL] [Abstract][Full Text] [Related]
38. Switching Among Biosimilars: A Review of Clinical Evidence. Allocati E; Godman B; Gobbi M; Garattini S; Banzi R Front Pharmacol; 2022; 13():917814. PubMed ID: 36091837 [TBL] [Abstract][Full Text] [Related]
39. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability. Zhou X; Chen Z; Bi X Drug Des Devel Ther; 2021; 15():2987-2998. PubMed ID: 34267501 [TBL] [Abstract][Full Text] [Related]